CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher?

Hagen M, Wirsching A, Bohr D, Taubmann J, Müller F, Mackensen A, Grieshaber Bouyer R, Schett G (2024)


Publication Type: Journal article

Publication year: 2024

Journal

DOI: 10.1007/s00393-024-01514-x

Abstract

Autoreactive B‑cells play a key role in the pathogenesis of autoimmune diseases, such systemic lupus erythematosus (SLE). An efficient depletion of B‑cells therefore plays a special role in autoimmune diseases, especially in cases with a severe course of the disease. Treatment with chimeric antigen receptor (CAR) T‑cells, which was originally developed for the treatment of B‑cell lymphomas and leukemias, provides the possibility to deplete B‑cells even in deep tissues. The initial results from case series with this procedure for SLE, myositis and systemic sclerosis were very positive. This review article gives an overview of the course, mechanism of action, results so far and the research agenda of CAR T‑cell therapy in autoimmune diseases.

Authors with CRIS profile

How to cite

APA:

Hagen, M., Wirsching, A., Bohr, D., Taubmann, J., Müller, F., Mackensen, A.,... Schett, G. (2024). CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher? Zeitschrift für Rheumatologie. https://doi.org/10.1007/s00393-024-01514-x

MLA:

Hagen, Melanie, et al. "CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher?" Zeitschrift für Rheumatologie (2024).

BibTeX: Download